Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
Not Applicable
Completed
- Conditions
- Allergic Asthma
- Interventions
- Registration Number
- NCT00736801
- Lead Sponsor
- University of Rostock
- Brief Summary
BDNF has been linked to the pathogenesis of airway hyperresponsiveness in asthma. In this trial, the impact of a treatment with salmeterol and salmeterol / fluticasone on BDNF concentrations will be assessed in patients with asthma. The investigators hypothesize that salmeterol impacts on BDNF concentrations in patients with asthma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
- Age > 18 years, a physician's diagnosis of allergic asthma
- A documented sensitization to aero-allergens (pollen, animal hair, or house dust mite)
- A pre-bronchodilator forced expiratory volume in the first second (FEV1) > 80 % of the predicted value (% predicted), a provocative concentration of histamine causing a 20 % fall in FEV1 (PC20) of < 8 mg histamine / ml
Exclusion Criteria
- No regular treatment (only short-acting inhalers on demand were allowed)
- No history of or evidence for any other chronic disease than asthma
- No history of smoking, absence of any signs or symptoms of an infection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A Salmeterol and Salmeterol / Fluticasone Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.
- Primary Outcome Measures
Name Time Method BDNF concentrations in serum, platelets and plasma 2006 - 2007
- Secondary Outcome Measures
Name Time Method Airway hyperresponsiveness 2006 - 2007
Trial Locations
- Locations (1)
University of Rostock
🇩🇪Rostock, Germany